Cite
APA Citation
Qin, S., Finn, R., Kudo, M., Meyer, T., Vogel, A., Ducreux, M., Macarulla, T., Tomasello, G., Boisserie, F., Hou, J., Li, C., Song, J., & Zhu, A. (n.d.). p-182Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095495542.0x000034